Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial-Onset or Primary Generalized Tonic-Clonic Seizures Monotherapy Age: Adult |
Dose: Oral – 25 mg Frequency: every 12 hours initially; may increase by 50 mg/day at weekly intervals to 200 mg every 12 hours Note: Hepatic impairment: Dosage adjustment may be needed. |
|
Indication: Partial onset seizures Adjunctive therapy Age: Adult |
Dose: Oral – 25-50 mg/day Frequency: initially; increase by 25-50 mg/day at weekly intervals to 100-200 mg every 12 hours Note: Hepatic impairment: Dosage adjustment may be needed. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Partial-Onset or Primary Generalized Tonic-Clonic Seizures Monotherapy Age: less than 2 years |
Dose: Oral – dose not established Note: Safety and efficacy not established |
|
Indication: Partial-Onset or Primary Generalized Tonic-Clonic Seizures Monotherapy Age: 2 to less than 10 years |
Dose: Oral – 25 mg Frequency: once at night for 1 week, then titrate dose over 5-7 weeks to target daily maintenance dose divided into every 12 hours Note: 150 mg/day minimum; 250 mg/day maximum |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Moderate to severe renal impairment |
Dose: Not specified – Doses should be halved Note: Dosage should be reduced by half in patients with moderate to severe renal impairment. |
|
Condition: Haemodialysis |
Dose: Not specified – Supplemental dose equal to about 1/2 of the daily dose Frequency: In divided doses Note: Supplemental dose should be given at the start and finish of haemodialysis. |
Administration
- Can be taken with or without food
- Take at same time daily
Side Effect
- Decrease in serum bicarbonate (7-67%)
- Dizziness (4-29%)
- Fatigue (9-16%)
- Ataxia (6-16%)
- Nervousness (9-18%)
- Paresthesia (1-11%)
- Psychomotor slowing (3-13%)
- Abnormal vision (2-13%)
- Anorexia (4-24%)
- Confusion (4-11%)
- Decreased memory (2-12%)
- Nausea (6-10%)
- Speech disorder (2-13%)
- Injury (14%)
- Abdominal pain (6-10%)
- Weight loss (4-9%)
- Diplopia (1-10%)
- Mood problems (Less than 6%)
- Pharyngitis (6%)
- Tremor (3-9%)
- Abnormal gait (3-8%)
- Apathy (1%)
- Asthenia (1-5%)
- Dry mouth (2%)
- Menorrhagia (1-2%)
- Skin disorder (2-3%)
- Taste change (2%)
- Edema (2%)
- Hypertension (1-2%)
- Syncope (1%)
- Bradycardia (1%)
- Pallor (1%)
- Angina
- Erythema
- Hepatic failure
- Hyperthermia
- Hypokalemia
- Neuropathy
- Toxic epidermal necrolysis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Antiepileptic drugs (e.g. phenytoin, carbamazepine, phenobarbital)
|
Decreases plasma concentration of topiramate
|
|
Phenytoin
|
Possible increase in levels
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity to Components
|
Can cause severe allergic reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.